…
Nutranomics, Inc. engages in the research, development, and sale of nutritional food products. It offers approximately 480 nutritional supplements, including formulating vitamin, mineral, herbal, and probiotic supplements. The company provides Nutritional Blood Analysis, a tool to examine the customer's blood cells on a video monitor, live, in real time; and the patented Assimilation Enhancing System that improves the absorption of nutrients. In addition, it offers educational services, including various types of analyses, trainings, certifications, and group presentations to individuals and industry professionals. The company distributes its products through sales representatives throughout North America and Asia, as well as through retail stores. Nutranomics, Inc. has a strategic partnership with Terra-Formance, LLC. The company was founded in 1995 and is headquartered in Salt Lake City, Utah.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Income before tax | - | -6.63M | -1.88M | - | - |
| Net income | - | -6.63M | -1.89M | - | - |
| Gross profit | - | -3.08M | -1.06M | - | - |
| Ebit | - | -4.13M | -1.83M | -0.60M | -0.57M |
| Ebitda | - | -4.01M | -1.57M | - | - |
| Depreciation and amortization | 0.17M | 0.12M | 0.26M | - | - |
| Operating income | - | -8.47M | -1.83M | - | - |
| Other operating expenses | - | 11.31M | 3.59M | - | - |
| Interest expense | - | 0.46M | 0.05M | 0.00M | 0.00M |
| Income tax expense | - | - | 0.00M | - | - |
| Total revenue | - | 2.85M | 1.76M | - | - |
| Total operating expenses | - | 5.39M | 0.78M | - | - |
| Cost of revenue | - | 5.92M | 2.82M | - | - |
| Total other income expense net | - | 1.84M | -0.05M | - | - |
| Net income applicable to common shares | - | - | - | -0.95M | -2.24M |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Total assets | - | 18.03M | 16.55M | - | - |
| Other current assets | - | 0.11M | 0.01M | - | - |
| Total liab | - | 28.59M | 19.34M | - | - |
| Total stockholder equity | - | -10.55M | -2.79M | - | - |
| Other current liab | - | 8.31M | -0.01M | 2.03M | 1.57M |
| Common stock | - | 1.40M | - | 4.12M | 2.16M |
| Retained earnings | - | -9.50M | -2.87M | -12.37M | -11.42M |
| Other assets | - | 0.00M | - | - | - |
| Cash | - | 0.34M | 0.33M | - | - |
| Total current liabilities | - | 15.35M | 5.87M | 7.08M | 6.39M |
| Net debt | - | 19.40M | 14.77M | - | - |
| Short term debt | - | 5.68M | 5.87M | - | - |
| Short long term debt total | - | 14.82M | 15.11M | - | - |
| Other stockholder equity | - | -11.58M | 0.08M | - | - |
| Total current assets | - | 2.74M | 1.54M | 0.03M | 0.03M |
| Net tangible assets | - | - | - | -7.06M | -6.36M |
| Net receivables | - | 1.15M | 0.18M | - | - |
| Inventory | - | 1.14M | 1.01M | - | - |
| Accounts payable | - | 1.37M | 0.02M | 0.55M | 0.53M |
| Accumulated other comprehensive income | - | -1.40M | - | - | - |
| Non currrent assets other | - | -0.00M | - | - | - |
| Non current assets total | - | 15.30M | 15.01M | - | - |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Change to liabilities | - | - | - | 0.24M | 0.16M |
| Total cashflows from investing activities | - | 2.97M | -0.43M | - | - |
| Net borrowings | - | - | - | 0.02M | 0.17M |
| Total cash from financing activities | - | 1.56M | 2.45M | 0.57M | 0.17M |
| Change to operating activities | - | - | - | - | 0.05M |
| Net income | - | -4.59M | -1.89M | -0.95M | -2.24M |
| Change in cash | - | 0.01M | 0.33M | 0.00M | 0.00M |
| Begin period cash flow | 0.34M | 0.33M | 0.00M | - | 0.09M |
| End period cash flow | 0.34M | 0.34M | 0.33M | - | - |
| Total cash from operating activities | - | -4.52M | -1.92M | -0.57M | -0.17M |
| Depreciation | - | 0.12M | 0.26M | - | - |
| Other cashflows from investing activities | - | 3.24M | - | - | - |
| Change to inventory | - | -0.84M | -0.75M | - | 0.03M |
| Change to account receivables | - | -0.97M | -0.18M | - | - |
| Other cashflows from financing activities | - | 2.97M | 2.02M | - | - |
| Change to netincome | - | - | - | 0.13M | 1.78M |
| Capital expenditures | 0.00M | 0.27M | 0.43M | 0.00M | 0.00M |
| Change in working capital | - | -1.09M | -0.29M | - | - |
| Other non cash items | - | 1.04M | 0.00M | - | - |
| Free cash flow | - | -5.95M | -2.35M | - | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.23 0.70% |
32.85 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.42 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
21.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-0.54 1.24% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Nutranomics, Inc. engages in the research, development, and sale of nutritional food products. It offers approximately 480 nutritional supplements, including formulating vitamin, mineral, herbal, and probiotic supplements. The company provides Nutritional Blood Analysis, a tool to examine the customer's blood cells on a video monitor, live, in real time; and the patented Assimilation Enhancing System that improves the absorption of nutrients. In addition, it offers educational services, including various types of analyses, trainings, certifications, and group presentations to individuals and industry professionals. The company distributes its products through sales representatives throughout North America and Asia, as well as through retail stores. Nutranomics, Inc. has a strategic partnership with Terra-Formance, LLC. The company was founded in 1995 and is headquartered in Salt Lake City, Utah.
11487 South 700 East, Salt Lake City, UT, United States, 84020
801-576-8350
1
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonathan Bishop | CEO & Member of Advisory Board | NA |
| Mr. Geoffrey Bazegian | Pres & Chief Revenue Officer | NA |
| Ms. Laura Riffel | Chief Operations Officer | NA |
| Mr. Neil Zoller | Sr. VP of Agricultural Supply Chain | NA |
| Dr. Edward J. Eyring II, M.D. | Gen. Mang. | 1967 |
| Mr. Geoffrey Bazegian | President & Chief Revenue Officer | NA |
| Mr. Neil Zoller | Senior Vice President of Agricultural Supply Chain | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.